Summary The chemosensitising effects of poly(ethylene oxide)-poly(propylene oxide)-poly-(ethylene oxide) (PEO-PPO-PEO) block copolymers (Pluronic) in multidrug-resistant cancer cells has been described recently (Alakhov VY, Moskaleva EY, Batrakova EV, Kabanov AV 1996, Biocon. Chem., 7, 209). This paper presents initial studies on in vivo evaluation of Pluronic copolymers in the treatment of cancer. The anti-tumour activity of epirubicin (EPI) and doxorubicin (DOX), solubilised in micelles of Pluronic L61, P85 and F108, was investigated using murine leukaemia P388 and daunorubicin-sensitive Sp2/0 and -resistant Sp2/0DNR myeloma cells grown subcutaneously (s.c.). The study revealed that the lifespan of the animals and inhibition of tumour growth were considerably increased in mice treated with drug/copolymer compositions compared with animals treated with the free drugs. The anti-tumour activity of the drug/copolymer compositions depends on the concentration of the copolymer and its hydrophobicity, as determined by the ratio of the lengths of hydrophilic PEO and hydrophobic PPO segments. The data suggest that higher activity is associated with more hydrophobic copolymers. In particular, a significant increase in lifespan (TIC> 150%) and tumour growth inhibition (>90%) was observed in animals with Sp2/0 tumours with EPI/P85 and DOX/L61 compositions. The effective doses of these compositions caused inhibition of Sp2/0 tumour growth and complete disappearance of tumour in 33-50% of animals. Future studies will focus on the evaluation of the activity of Pluronic-based compositions against human drug-resistant tumours.
Various drug delivery systems are actively being developed to decrease toxicity and increase the activity of chemotherapeutic agents. Examples are antibodies (Reilly, 1995) , liposomes (Mayer et al., 1995; Gabizon, 1993) , polymerdrug conjugates (Maeda et al., 1992; Duncan, 1992) , and microspheres (Doughty et al., 1995) . Micelles of block copolymers, containing hydrophilic and hydrophobic chain segments, have recently attracted considerable attention as a novel class of drug delivery systems (Bader et al., 1984; Kabanov et al., 1989; Yokoyama et al., 1990) . These micelles represent self-assembled structures with a core formed by the hydrophobic segments and a corona formed by the hydrophilic segments. A great variety of drugs can be non-covalently incorporated into such micelles by simple mixing with the block copolymer solutions (Kabanov et al., 1992) . Drug molecules can also be covalently linked to the repeating units of the copolymer segment (Bader et al., 1984) . In both cases, the drug incorporates into the micelle core, where it is masked from the external media by the hydrophilic corona, which usually consists of non-toxic and non-immunogenic poly(ethylene oxide) (PEO) chains. As a result, the metabolic stability of such drugs, for example doxorubicin, can be greatly increased (Yokoyama et al., 1991) . The PEO corona also produces micelles with long circulation times in the body similar to the 'stealth' liposomes with PEO-modified surface . The size of the micelles is similar to that of viral particles (below 50 nm), so that they are much smaller than most other self-assembled delivery systems. This presumably provides for improved penetration of tissues (Kabanov et al., 1992) . Finally, the copolymer structure allows easy attachment of vector molecules, such as antibodies, to the end groups of PEO segments, allowing targeting of these systems in vivo (Kabanov et al., 1992) .
Most early work in this area concentrated on drugs that were covalently conjugated to a PEO-polypeptide copolymer (Bader et al., 1984; Yokoyama et al., 1990 Yokoyama et al., , 1991 . Recently, these studies shifted to the systems in which the drug is noncovalently incorporated in the micelles Dunn et al., 1994; Draper et al., 1995; Kwon et al., 1993 Kwon et al., , 1995 La et al., 1996) . In contrast to the conjugates, these systems retain the drug by hydrophobic interactions permitting easy release into the cell. They were first used to target a central nervous system (CNS) agent, haloperidol, across the blood-brain barrier to the brain (Kabanov et al., 1989 (Kabanov et al., , 1992 . In this work the drug was solubilised in Pluronic micelles coupled to targeting antibodies. This approach resulted in an increase in in vivo neuroleptic activity several hundred-fold. Another striking result was obtained during a study of the Pluronic effects on the activity of antineoplastic agents in multidrug-resistant (MDR) cancer cells, expressing the P-glycoprotein (P-gp) drug efflux pump (Alakhov et al., 1996a,b) . It was found that the copolymers 'hypersensitise' the resistant cells, with the result that the cytotoxic drug activity was increased by about three orders of magnitude.
Drug transport data suggest that MDR reversal in the presence of these copolymers involves inhibition of the P-gp efflux system leading to increased drug accumulation in the MDR cells (Alakhov et al., 1996a,b) . However, in contrast to most known P-gp inhibitors, which usually increase MDR cell sensitivity to the levels observed with non-MDR cells, these copolymers hypersensitised the MDR cells. Therefore, Pluronic copolymers may be the most potent sensitisers of MDR cancers, a unique feature of these delivery systems. The chemosensitising effects of the Pluronic copolymers depended critically on their hydrophobic -lipophilic balance (HLB) (Alakhov et al., 1996a) . This paper investigates anti-tumour effects of doxorubicin (DOX) and epirubicin (EPI) formulated with Pluronic L61, P85 and F108 copolymers with varying hydrophobicity, using s.c. drug-sensitive and -resistant murine myelomas Sp2/0 and Sp2/oDNR, and leukaemia P388.
Materials and methods Drug/copolymer compositions Pluronic L61, P85 and F108 (abbreviated below as 'L61', 'P85' and 'F108' respectively) were purchased from Serva (Germany) and used without further purification. They were dissolved at various concentrations (0.1 to 1%) in phosphatebuffered saline (PBS) at 4°C and then sterilised by filtration through a 0.2 gm filter. Drug/copolymer compositions were obtained by dissolving EPI (Farmitalia Carlo Erba, Milan, Italy) or DOX (Farreign, Moscow, Russia) in the copolymer solutions. These compositions were incubated for 30 min at 37°C before administration to mice.
Physicochemical characterisation of drug/copolymer compositions The critical micelle concentrations (CMCs) of L61, P85 and F108 were determined using a pyrene solublisation technique previously described by Kabanov et al. (1995) . The partitioning of anthracyclines in the micelles was studied by fluorescence spectroscopy (Alakhov et al., 1996a) . Briefly, 0.12 ,ug ml-1 of the drug was dissolved in copolymer solutions of various concentrations, and the drug fluorescence spectra (4ex=471 nm) were recorded using a Shimadzu 500 spectrofluorimeter at 37°C. The partitioning coefficients, P, were determined from the dependencies of drug fluorescence at Aem = 547 nm on the copolymer concentration using the linear plots: Below CMC ao values were determined for the initial drug/copolymer compositions (1:1) and for the hypothetical conditions of 10-fold dilution of these compositions in plasma (1:10). Table II . In all cases the concentrations of copolymers in the compositions were significantly higher than the CMCs. Therefore, the micelles were present in these systems along with the equilibrium concentration of the single chains ('unimers') of the copolymer (which approximates CMC). Further, in these systems the drug molecules are partitioned between the micellar microphase and bulk aqueous phase. The fraction of the micelle-incorporated drug, a, is dependent on the copolymer concentration and the partitioning coefficient (Kabanov et al., 1995) :
where C..,, and CO are the concentration of the micelleincorporated drug and the total concentration of the drug in the system respectively. The P-values were determined for various copolymers using fluorescence measurements as described in Materials and methods. The values of a were calculated using equation (5) for the initial drug/copolymer compositions and for the hypothetical conditions of a 10-fold dilution of these compositions in plasma (Table II) .
Activity against s.c. Sp2/0 tumour The data on the drug effects on the lifespan of mice with Sp2/ 0 tumour are summarised in Table III. A dose of 7.5 mg kg-' free EPI moderately increased the lifespan of the treated group; the effects of the lower doses were insignificant, and higher doses caused toxic death (not shown in Table III ). The ) and groups (n=23, _) treated with 1.25 and 2.5mgkg-' DOX/L61 (0.25%) and (0.5%).
Chemosensitising effects of copolymers EV Batrakova et al 1549 free DOX was ineffective in doses up to 3.5 mg kg-1, while 5.0 mg kg-' and larger doses caused toxic death. Further, TI indexes, both for free EPI and DOX, did not exceed 17% and were not statistically significant. In contrast to the free drugs, several drug/copolymer compositions revealed good activity in lifespan and tumour growth tests. Specifically, EPI/P85 revealed good activity against Sp2/0 tumours at 7.5 mg kg-' and was moderately active at 5 mg kg-' (Table   III) . In these cases the TI index was as high as 99.6% and 66.8%, respectively, with a level of significance of P<0.01. Further, 33.3% of long-term survivors were observed in the group treated with 7.5 mg kg-i EPI/P85. The kinetics of the tumour growth presented in Figure la suggests that this dose exhibited the highest anti-tumour effect causing the reversal of the Sp2/0 growth at about 2 weeks after first administration of the drug. About 2 weeks after the last administration, relapse of the tumour was observed in four animals, which accounted for the tumour volume elevation. However, two -long-term survivors did not demonstrate tumour relapse over the entire study period. Even more pronounced effects were observed with DOX/L61 (0.5%) and DOX/L61 (0.25%) compositions. In these cases substantial activity was observed with 1.25 mg kg-' and 2.5 mg kg-' doses. To illustrate the effects of these compositions on lifespan, a histogram is presented in Figure 2 comparing the lifespan of the control group and a combined group of animals treated with 1.25 mg kg-' and 2.5 mg kg-' DOX/ L61 (0.5%) and DOX/L61 (0.25%). The survival time distribution in the control group (n=31) is close to normal, with the MSTc being 31.9 (± 13.4 s.d.). One animal in the control group died on day 7, which for the treated group would be considered as 'toxic' death; one animal was considered as a long-term survivor. The significant increase in the survival times in the combined treated group (n=23) was observed, with MSTT being 49.4 (±14.0 s.d.), and T/ C= 155 (P= 1.7 x 10-5). Five animals in the combined treated group qualified as long-term survivors, and no toxic death was observed. The best effects on the lifespan were observed in the individual groups treated with 2.5 mg kg-' DOX/L61 (0.25%). In the groups treated with 2.5 mg kg-' DOX/L61 (0.25%) and DOX/L61 (0.5%), the TI indexes were as high as 99.4% and 98.0%, and the differences between tumour volumes in the treated and control groups were statistically significant (P<0.002). The kinetics of tumour growth in these cases was similar to that observed for EPI/P85, revealing the reversal of tumour growth with subsequent relapse after interruption of drug administration (Figure 1 b and c) . In the case of 2.5 mg kg-' DOX/L61 (0.25%), three long-term survivors were completely cured of the tumour. The effects of DOX/L61 compositions were dependent on the copolymer concentration. A dose of 2.5 mg kg -' DOX/L61 (0.1%) revealed only moderate activity in the lifespan test (Table III) and caused much less significant effects on tumour growth compared with the effects of the compositions with higher copolymer content (Figure ld) . More modest effects (compared with L61-and P85-based compositions) were observed with DOX/F108. A dose of 2 mg kg-' DOX/F108 Abbreviations are the same as in Table III . caused some decrease in the lifespan. The effects of 3.5 mg kg-' and 5.0 mg kg-' were not statistically significant, and 7.5 mg kg-' (not shown in Table III respectively. Further, the good activity in inhibition of tumour growth (TI= 92.2%, P<0.002) was observed with the 5.0 mg kg-' dose of DOX/F108 (Figure le) . Generally, the effective dose range of drug/copolymer compositions was lower compared with the free drug doses. However, the antitumour activity of these compositions was higher than the activity of the free drugs. These effects were evidently a result of formulating the drugs with the copolymers since copolymers alone did not significantly affect either the median survival time or the tumour growth (Table III and Figure 1 ).
Activity against s.c. P388 tumour The effects of free drug and drug/copolymer on s.c. P388 were compared using the example of DOX and DOX/P85. The effects of DOX on the lifespan (Table IV) This resistance was reversed in the presence of P85 (Table V) . Further, the Sp2/0DNR tumour maintained the resistance during the entire period of growth in mice (Table V) and 2.5mgkg-1 (*). Abbreviations are the same as in Table III.   AA   L   0 0   1551 should be noted, however, that 5 mg kg-' free DOX and EPI revealed inhibition of tumour growth in vivo (TI of 45% and 41% respectively), which was higher than the effects of these drugs on the parental Sp2/0 tumour. The growth rate of Sp2/ 0DNR was 2-5 times lower than that of Sp2/0, which may explain why the free drug was more active against Sp2/0DNR tumour in vivo. The effects of the free drugs and drug/ copolymer compositions on the lifespan were not significant with the exception of 1.0 mg kg-' EPI/P85, which revealed moderate activity in this test (Table VI) . However, the effects of this composition on tumour growth were moderate ( Figure  3a) , with the TI index (=54%) barely exceeding that observed with the free drug. The best results on tumour inhibition were observed with DOX/L61 (0.5%). As shown in Figure 3a , reversal of tumour growth was observed with 2.5 mg kg-' and 5 mg kg-' of this composition, yielding a TI index approximating 90% (P<0.01).
Discussion
One major result of this work is that Pluronic copolymers significantly increase the anti-tumour effects of anthracycline antibiotics in vivo observed in conditions of high tumour inoculum. Contrary to previous observations with DOX that was covalently attached to a block copolymer carrier (Yokoyama et al., 1990 (Yokoyama et al., , 1991 , the effective doses of noncovalently incorporated anthracyclines were the same or lower than those of the free drugs. Furthermore, the increase in the lifespan and inhibition of tumour growth were observed with the effective doses of drug/copolymer compositions. Given the amount of compositions involved in this study, as well as the dependence of their activity on several factors, it is likely that the anti-tumour effects can be further improved by optimising the type of copolymer, its concentration as well as administration schedule. Nevertheless, based on the data of Sp2/0 myeloma, one can make a preliminary assumption that higher activity in inhibition of tumour growth is associated with more hydrophobic copolymers. Specifically, the EPI/P85 and DOX/L61 compositions were very active in the lifespan and tumour inhibition tests.
One concern about drugs conjugated to block copolymers is their slow or insignificant release from the polymeric carrier (M Yokoyama, personal communication). The situation is totally different in the case of the non-covalent compositions studied in this paper. Indeed, in these systems both the block copolymer and drug molecules are partitioned and dynamically exchanged between the bulk aqueous phase and micelle species (Kabanov et al., 1995; Alakhov et al., 1996a) . The equilibrium partitioning of the copolymer is characterised by the CMC: above this concentration both the micelles and the unimers of the copolymer are present in the system. The drug molecules are also partitioned between the micelles and bulk aqueous phase, with the fraction of the micelle-incorporated drug expressed by equation (5). Two major conclusions can be made based on this consideration. First, if the drug-containing micelles accumulate in the target tissue then they would serve as a 'depot' for the release of the free drug, which does not involve cleavage of the chemical bonds between drug and copolymer. This underlies a major difference between non-covalent formulations and the drugs conjugated to the polymers, where the release of the drug from the carrier in the active state requires its cleavage into the target cell (Subr et al., 1992) . Second, the dilution of the copolymer micelles in the body fluids must lead to the decrease in the fraction of the drug micellar form and increase in the free drug form respectively. For example, the data presented in Table II suggest that 10-fold dilution of DOX/L61 (0.1%) would result in decrease of the L61 concentration below CMC and, thus, eliminate the micelles from circulation. The same dilution would preserve the micelles in the case of DOX/L61 (0.25%) and (0.5%), which will still retain substantial portions of the drug. It is possible that dilution effects contribute to the dependence of the antitumour effects on the drug concentration. This consideration, however, does not account for the possible effects of the copolymer structure on the pharmacokinetics and biodistribution picture. It was previously demonstrated that the biodistribution of the fluorescent dye incorporated in Pluronic micelles was strongly dependent on copolymer structure (Kabanov et al., 1992) . Therefore, the molecular parameters of the copolymers may cause complex effects on drug performance and result in the differences in anti-tumour activities exhibited. The study of these effects is currently in progress in our laboratories.
